Keywords: Vernalis, Servier, Oncology collaboration

Third deal with Servier for Vernalis

Article | 17 January 2012

Print This

UK drug developer Vernalis (LSE: VER) and independent French pharma company Laboratories Servier have entered into a new three-year joint ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in